Evolus, Inc. (EOLS)
USD 10.27
(7.65%)
USD 10.27
(7.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.68 Million USD | 17.1% |
| 2022 | -74.41 Million USD | -58.97% |
| 2021 | -46.81 Million USD | 71.28% |
| 2020 | -163.01 Million USD | -81.06% |
| 2019 | -90.03 Million USD | -92.11% |
| 2018 | -46.86 Million USD | -946.14% |
| 2017 | -4.48 Million USD | 77.67% |
| 2016 | -20.06 Million USD | 35.51% |
| 2015 | -31.11 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -13.1 Million USD | -10.8% |
| 2024 Q2 | -11.35 Million USD | 13.42% |
| 2023 Q4 | -11.83 Million USD | 30.09% |
| 2023 FY | -61.68 Million USD | 17.1% |
| 2023 Q1 | -14.79 Million USD | -12.36% |
| 2023 Q2 | -18.14 Million USD | -22.64% |
| 2023 Q3 | -16.92 Million USD | 6.71% |
| 2022 Q2 | -23.47 Million USD | -34.11% |
| 2022 Q1 | -17.5 Million USD | 3.72% |
| 2022 FY | -74.41 Million USD | -58.97% |
| 2022 Q4 | -13.16 Million USD | 35.08% |
| 2022 Q3 | -20.27 Million USD | 13.61% |
| 2021 FY | -46.81 Million USD | 71.28% |
| 2021 Q4 | -18.17 Million USD | 6.46% |
| 2021 Q1 | 6.4 Million USD | 105.78% |
| 2021 Q2 | -15.6 Million USD | -343.73% |
| 2021 Q3 | -19.43 Million USD | -24.56% |
| 2020 Q3 | -11.45 Million USD | 45.76% |
| 2020 FY | -163.01 Million USD | -81.06% |
| 2020 Q4 | -110.69 Million USD | -866.0% |
| 2020 Q1 | -19.73 Million USD | -36.03% |
| 2020 Q2 | -21.12 Million USD | -7.04% |
| 2019 FY | -90.03 Million USD | -92.11% |
| 2019 Q4 | -14.5 Million USD | 46.23% |
| 2019 Q3 | -26.98 Million USD | 28.17% |
| 2019 Q2 | -37.56 Million USD | -242.3% |
| 2019 Q1 | -10.97 Million USD | 11.79% |
| 2018 Q3 | -11.83 Million USD | 28.01% |
| 2018 Q2 | -16.43 Million USD | -166.68% |
| 2018 Q4 | -12.44 Million USD | -5.17% |
| 2018 FY | -46.86 Million USD | -946.14% |
| 2018 Q1 | -6.16 Million USD | -238.53% |
| 2017 Q3 | -2.63 Million USD | -14.72% |
| 2017 FY | -4.48 Million USD | 77.67% |
| 2017 Q2 | -2.29 Million USD | 42.57% |
| 2017 Q4 | 4.44 Million USD | 268.87% |
| 2017 Q1 | -3.99 Million USD | -6.81% |
| 2016 FY | -20.06 Million USD | 35.51% |
| 2016 Q1 | -6.08 Million USD | 0.0% |
| 2016 Q2 | -6.08 Million USD | 0.0% |
| 2016 Q3 | -4.16 Million USD | 31.59% |
| 2016 Q4 | -3.74 Million USD | 10.02% |
| 2015 FY | -31.11 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 228.097% |
| Embecta Corp. | 70.4 Million USD | 187.621% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 428.479% |
| Dynavax Technologies Corporation | -6.38 Million USD | -865.488% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 70.521% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 247.027% |
| PainReform Ltd. | -9.34 Million USD | -560.156% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -683.799% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1268.939% |
| SCYNEXIS, Inc. | 67.04 Million USD | 192.011% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -1890.781% |
| Cosmos Health Inc. | -18.54 Million USD | -232.665% |
| Journey Medical Corporation | -3.85 Million USD | -1500.96% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -1268.939% |
| Safety Shot Inc | -15.08 Million USD | -308.969% |
| Alpha Teknova, Inc. | -36.78 Million USD | -67.713% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 55.836% |
| Bright Green Corporation | -13.12 Million USD | -369.886% |
| Procaps Group, S.A. | 42.54 Million USD | 245.005% |
| Theratechnologies Inc. | -23.95 Million USD | -157.482% |
| Harrow Health, Inc. | -24.41 Million USD | -152.693% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -1175.801% |
| Biofrontera Inc. | -20.13 Million USD | -206.418% |
| DURECT Corporation | -27.62 Million USD | -123.302% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 4787.31% |
| Cronos Group Inc. | -73.96 Million USD | 16.6% |
| OptiNose, Inc. | -35.48 Million USD | -73.844% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 93.845% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -46.176% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 357.924% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 1347.422% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 39132.987% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -882.352% |
| Radius Health, Inc. | -25.79 Million USD | -139.173% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -900.883% |
| ProPhase Labs, Inc. | -16.78 Million USD | -267.566% |
| Phibro Animal Health Corporation | 2.41 Million USD | 2653.187% |
| Procaps Group S.A. | 42.54 Million USD | 245.005% |
| Alvotech | -551.73 Million USD | 88.82% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -500.165% |
| Viatris Inc. | 54.7 Million USD | 212.77% |
| Rockwell Medical, Inc. | -8.43 Million USD | -630.952% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -289.327% |
| SIGA Technologies, Inc. | 68.06 Million USD | 190.622% |
| Tilray Brands, Inc. | -244.98 Million USD | 74.82% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 613.485% |
| Shineco, Inc. | -22.44 Million USD | -174.778% |
| PetIQ, Inc. | 2.13 Million USD | 2994.65% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -1333.922% |
| Incannex Healthcare Limited | -18.45 Million USD | -234.173% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 124.704% |
| Alimera Sciences, Inc. | -20.13 Million USD | -206.403% |
| Silver Spike Investment Corp. | 7.34 Million USD | 940.383% |
| Assertio Holdings, Inc. | -331.94 Million USD | 81.417% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -835.653% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -655.648% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -244.628% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -207.544% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 61.513% |
| Hempacco Co., Inc. | -13.12 Million USD | -369.942% |
| Talphera, Inc. | -18.39 Million USD | -235.299% |
| Alvotech | -551.73 Million USD | 88.82% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 273.068% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 118.883% |
| Currenc Group, Inc. | -15.3 Million USD | -302.997% |
| Kamada Ltd. | 8.28 Million USD | 844.628% |
| Indivior PLC | 2 Million USD | 3184.25% |
| Evoke Pharma, Inc. | -7.79 Million USD | -691.615% |
| Flora Growth Corp. | -57.03 Million USD | -8.151% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -207.544% |
| HUTCHMED (China) Limited | 100.78 Million USD | 161.208% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 144.847% |
| Akanda Corp. | -32.27 Million USD | -91.123% |